Ratings by Janney (Paul Knight)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/15/2020 | Interpace Diagnostics Group Inc | IDXG | New Coverage | Buy (N/A) |
4.81 (1.42) |
-70.48% | Details | |
| 2/11/2020 | Fluidigm Corporation | FLDM | Maintain | Neutral (N/A) |
|
Details | ||
| 11/26/2019 | T2 Biosystems, Inc | TTOO | Downgrade | Neutral (Buy) |
1.42 (2.74) |
92.96% | Details | |
| 11/6/2019 | Fluidigm Corporation | FLDM | Downgrade | Neutral (Buy) |
5.11 (3.71) |
-27.4% | Details | |
| 9/12/2019 | T2 Biosystems, Inc | TTOO | Upgrade | Buy (Neutral) |
2.61 (1.42) |
-45.59% | Details | |
| 7/24/2019 | Champions Oncology | CSBR | Downgrade | Neutral (Buy) |
7.21 (5.06) |
-29.82% | Details | |
| 7/2/2019 | Bio-Techne Corp. | TECH | Upgrade | Buy (Neutral) |
208.49 (62.66) |
-69.95% | Details | |
| 6/28/2019 | Avid Bioservices | CDMO | Upgrade | Buy (Neutral) |
4.00 (7.32) |
83% | Details | |
| 6/14/2019 | Avantor Inc. | AVTR | New Coverage | Buy (N/A) |
18.19 (25.15) |
38.26% | Details | |
| 2/25/2019 | Danaher | DHR | Upgrade | Buy (Neutral) |
113.48 (245.80) |
116.6% | Details | |
| 1/29/2019 | OncoCyte Corp | OCX | Upgrade | Buy (Neutral) |
1.82 (2.44) |
34.07% | Details | |
| 1/3/2019 | Fluidigm Corporation | FLDM | Upgrade | Buy (Neutral) |
8.62 (5.11) |
-40.72% | Details | |
| 11/29/2018 | Veracyte, Inc | VCYT | Maintain | Buy (N/A) |
|
Details | ||
| 11/2/2018 | PerkinElmer | PKI | Downgrade | Neutral (Buy) |
86.48 (115.24) |
33.26% | Details | |
| 10/31/2018 | Veracyte, Inc | VCYT | Upgrade | Buy (Neutral) |
9.44 (12.13) |
28.5% | Details | |
| 10/30/2018 | Neogenomics | NEO | Maintain | Buy (N/A) |
|
Details | ||
| 10/3/2018 | Repligen | RGEN | Maintain | Buy (N/A) |
|
Details | ||
| 10/2/2018 | West Pharmaceutical | WST | Maintain | Buy (N/A) |
|
Details | ||
| 9/10/2018 | OncoCyte Corp | OCX | Maintain | Buy (N/A) |
|
Details |
